Compare SCHL & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | AQST |
|---|---|---|
| Founded | 1920 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.7M | 809.3M |
| IPO Year | 1987 | 2018 |
| Metric | SCHL | AQST |
|---|---|---|
| Price | $29.45 | $5.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $37.00 | $10.00 |
| AVG Volume (30 Days) | 252.1K | ★ 2.4M |
| Earning Date | 12-18-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,613,900,000.00 | $43,397,000.00 |
| Revenue This Year | $3.78 | N/A |
| Revenue Next Year | $4.56 | $52.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.97 | N/A |
| 52 Week Low | $15.77 | $2.12 |
| 52 Week High | $31.86 | $7.55 |
| Indicator | SCHL | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 46.15 |
| Support Level | $27.08 | $5.99 |
| Resistance Level | $28.75 | $6.44 |
| Average True Range (ATR) | 1.07 | 0.33 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 50.63 | 20.40 |
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.